Taken together, there is conclusive evidence that the mARC1 p.A165T variant conveys protection against NAFLD and its progression toward nonalcoholic steatohepatitis (NASH). This evidence concerns the gene MTARC1 and metabolic dysfunction-associated steatohepatitis.